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An action plan for 
pan-European defence 
against new SARS-CoV-2 
variants
COVID-19 cases are very high across 
Europe. Current measures are not 
reducing virus spread sufficiently, 
and new severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) 
variants are emerging. The B.1.1.7 
and B1.351 variants, first identified in 
the UK and South Africa, respectively, 
have spread to many European 
countries.1–5 Although the biological 
properties of these variants are yet 
to be characterised, epidemiological 
data suggest they have a higher 
transmissibility than the original 
variant.6,7 These viral properties could 
increase the effective reproduction 
number R in the population. In the 
case of B.1.1.7, estimates suggest 
R could increase from 1 to about 
1.4 with no change in population 
behaviour.3,4 If true, many countries 
that have succeeded in reducing R 
to 1 or less will be confronted with 
a novel wave of viral spread despite 
the current measures.8,9 Once a more 
contagious variant has established 
itself, stabilising the number of new 
infections will become increasingly 
difficult.
Despite the availability of effective 
vaccines, production to meet 
demand and roll-out of vaccination 
programmes will take months. 
Countries will have to manage high 
case numbers and their adverse 
impact for several months to come. 
With slowly increasing population 
immunity and evolutionary selection 
pressure on the virus, the emergence 
of new SARS-CoV-2 variants will 
continue, potentially leading to more 
contagious variants, and perhaps even 
variants for which existing vaccines 
are less effective. Such variants could 
quickly exacerbate the crisis, long 
before enough people are vaccinated. 
While awaiting experimental data 
to understand the new variants, 
pan-European decisions have to be 
made, and actions have to be taken 
immediately to contain the spread of 
new variants.
If measures are not taken to prevent 
the spread of novel variants with 
selective advantages, case numbers 
and hospital admissions will increase. 
A surge in cases could lead to the 
breakdown of health-care systems. 
In many countries, hospitals can no 
longer deliver care of the usual quality 
to all patients. Many intensive care 
units are already beyond capacity, 
and non-urgent procedures have 
been postponed for weeks or months. 
Panel: Core measures to prevent the spread of SARS-CoV-2 in Europe
Achieve and maintain low case numbers with a clear prevention strategy
• Define clear targets and rekindle motivation: clearly define the targets that need 
to be met for measures to be lifted and explain the rationale behind them; 
convincingly convey that the fight against the pandemic needs a collective effort 
that is in the interest of every citizen; and ensure adequate social and economic 
support for those in need.
• Act early: implement mitigation measures before case numbers spike.
• Reduce the number of physical contacts: meet as few different people as possible; 
implement and improve home-office and online schooling; small, stable social 
bubbles, and stable groups at home and at work should be preferred over 
alternating contacts.
• Prevent contagion by individual measures such as physical distancing, hygiene, 
face masks, ventilation, and use of filters, avoiding closed and crowded spaces 
and staying at home when experiencing symptoms; provide FFP2 masks to those 
in need and to all who cannot work from home.
Monitor the spreading of the virus and of individual variants
• Test, trace, isolate, support: enforce mandatory isolation of people with 
confirmed infections and encourage preventive quarantine of suspected cases; 
support affected individuals and families.
• Screen and test preventively: offer tests at schools and workplaces at no cost to 
detect outbreaks early and protect people; increase testing capacity to meet 
demand; use waste-water surveillance to detect local surges.
• Increase genetic sequencing and PCR-based detection of the B.1.1.7 variant, 
as well as other variants of SARS-CoV-2.
Stop the virus at borders and protect the vulnerable
• Reduce travel within and across national borders, and require tests and 
quarantine for cross-border travellers; tests should be required 24 h before travel 
and 7–10 days after travel; quarantine anyone arriving from countries with high 
local COVID-19 transmission or suspicious variants.
• Improve the protection of, and support for, the old and vulnerable groups; foster 
European exchange about successful strategies and measures to speed up the 
progress.
Increase the efficacy and pace of vaccination
• Speed up vaccination: improve vaccine supply, delivery, and allocation by mutual 
learning and international cooperation; coordinate efforts to scale up the 
production of vaccines.
• Monitor infections among vaccinated people to detect potential reinfection with 
new variants or deficient vaccination management as soon as possible.
• Answer urgent questions through international cooperation; research ways to 
improve vaccination regimes to optimise logistics, or increase willingness to be 
vaccinated using data from multiple countries.
SARS-CoV-2=severe acute respiratory syndrome coronavirus 2. Further details are available in the appendix.
See Online for appendix
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The longer restrictions last, and the 
less effective they become, the more 
depleted people’s psychological, social, 
and economic resources become. 
Where novel variants require even 
stricter and longer measures than 
existing measures, it is of utmost 
importance to ensure that people with 
particularly heavy burdens receive 
financial and social support, that 
social burdens are justly distributed, 
and that mental health services 
meet the increasing demand to cope 
with bereavement, isolation, loss of 
income, fear, alcohol and drug misuse, 
insomnia, and anxiety as a result of the 
pandemic and lockdown strategies. 
Contextual factors, and factors 
affecting risk behaviour such as risk 
perception, must also be considered.
The core principles of action are 
to avoid importing new variants, to 
prevent their spread, and to improve 
molecular surveillance. The earlier and 
more effectively countries act, the 
earlier the restrictions can be relaxed. 
All types of measures ought to be 
coordinated and synchronised across 
Europe. Every additional reduction 
of contagion (ie, of R) counts, as it 
reduces the necessary duration of strict 
measures more than proportionally.
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Delayed diagnosis and compromised 
care delivery for people with other 
diseases poses additional health risks, 
not just to patients with COVID-19, 
but for the whole population.
Health-care professionals and other 
frontline workers have already been 
working under extreme conditions for 
most of the past year, and this has had 
a severe impact on their physical and 
mental health. If variants like B.1.1.7 
lead to a new surge in cases, this could 
overwhelm health-care professionals 
and bring health-care systems to the 
breaking point. Ensuring that the 
burden on health-care professionals is 
alleviated while safeguarding system 
sustainability is of critical importance. 
Adequate support for these crucial 
forces might require additional funds.
Containment and mitigation 
become more challenging with the rise 
of a more infectious variant. Assuming 
that the B.1.1.7 variant does increase 
R from 1 to 1.4, then allowing it to 
spread without a change in population 
behaviour will mean case numbers 
double every week. Major efforts will 
be necessary to bring R back down to 
1 or less and to regain control. Acting 
before B.1.1.7 has spread widely 
means that those same major efforts 
could strongly reduce the number 
of new cases and slow down the 
establishment of B.1.1.7.
Europe needs to act now to delay 
and prevent any further spread 
of SARS-CoV-2, 8,9 particularly 
B.1.1.7, even in the absence of final 
experimental data. A clear plan for 
immediate pan-European action and 
rapid establishment of public health 
measures needs to be formulated since 
new variants with increased infectivity 
are likely to continue to arise. We 
suggest possible core measures in 
the panel. The guiding principle is 
to reduce case numbers as quickly as 
possible as this has strong advantages 
for health, society and economy. The 
joint action of all European countries 
will make each national and local effort 
more effective and impactful and 
safeguard public health across Europe.8
For translations see http://www.
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